Topical: SolarazeŽ

Topical gel formulation of diclofenac using Hyaluronan Induced Targeting (HIT) technology

Approved for treatment of pre-cancerous skin condition actinic keratosis

UK launch May 2001

German launch Aug 2001

US launch Jan 2002

US market potential estimate: US$250m

Resolution with Bioglan in Dec 2001

Bioglan paid SkyePharma US$12.5m

North American marketing rights transferred to Quintiles for further US$5m

Seeking new European marketing partner

(Quintiles/Bioglan)

Previous slide

Next slide

Back to first slide

View graphic version